SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could fall sharply in 2027 has fueled concern about pricing and sales for CorMedixs flagship product, alongside a steep selloff. Traders disagree over whether the warning signals lasting pressure or is a preliminary, DaVita-specific estimate that overstates the risk; some view the decline as panic selling and point to CMS reimbursement figures as a counterpoint.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas selection for S&P 500 inclusion is drawing attention, with traders anticipating demand from index-tracking funds while debating whether that buying is already priced in and could be followed by profit-taking. The discussion also weighs the inclusion-driven momentum against concerns about Oktas valuation and slower growth.

NEOS ETF Trust - NEOS Nasdaq 100 High Income ETF

NEOS Nasdaq 100 High Income ETF

A broader market and Nasdaq-led tech selloff has pressured QQQI, prompting many holders to add on the dip while others raise cash or worry about further downside. The debate is set against the ETFs appeal as a high-income, monthly-distribution fund and concerns that covered-call exposure can limit upside or leave the fund vulnerable in a downturn.

Cameco Corp. engages in the provision of uranium. It operates through the following segments: Uranium and Fuel Services. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Camecos Q3 report, including lower results and narrowed 2026 production guidance amid Cigar Lake production concerns, is driving the selloff. Traders are split between viewing the update and uranium-sector weakness as reasons for further downside and treating the pullback as an opportunity, citing long-term nuclear demand and firm uranium prices.

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Agenus is drawing attention for encouraging early BOT+BAL immunotherapy data, including high pathologic response rates in a small Phase 2 colon cancer cohort and reported activity in sarcoma. The community is divided: bulls see potential for the treatment and its broader platform, while skeptics point to small, nonrandomized studies, the need for Phase 3 validation, and dilution and execution concerns.

Mattel, Inc. engages in the ownership of children's and family entertainment franchises. It operates through the following segments: North America, International, and American Girl. The North America and International segments focus on marketing and selling toys and consumer products. The American Girl segment includes marketing, retailing, and publishing dedicated to its mission to help girls grow up with confidence and character. The company was founded by Elliot Handler, Ruth Handler, and Harold Matson in 1945 and is headquartered in El Segundo, CA.

Mattel, Inc.

Reported takeover interest from Authentic Brands Group, alongside activist pressure for Mattel to consider a sale, is driving the discussion; no formal deal is confirmed. Traders are weighing potential acquisition upside against the risk that the takeover buzz fades without a firm bid.

United States Natural Gas Fund LP. - United States Natural Gas Fund

United States Natural Gas Fund, LP

Mild-weather forecasts and ample storage are weighing on natural gas prices by tempering expectations for heating demand. Traders are split between bearish views citing a potentially warm winter and surplus inventories, and dip-buyers betting on colder forecasts or a winter-driven rebound.

FuelCell Energy, Inc. is an American clean energy technology company that delivers continuous, scalable baseload power for mission-critical applications globally. It engages in the development, design, production, construction, operation, and servicing of high-temperature fuel cells for clean electric power generation. The company’s fuel cell systems generate electricity directly at the point of use, enabling reliable, low-emission power for data centers, industrial facilities, utilities, and distributed generation customers. FuelCell Energy delivers commercially proven, modular, utility-scale systems backed by global fuel cell deployments approaching one gigawatt. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FCEL is under pressure after traders criticized CEO Jason Fews Bloomberg appearance and flagged his expectation of a delay in signing the Texas definitive contract, alongside uncertainty about the promised 100 MW production ramp. Some investors remain focused on potential data-center demand and the Newport project, while others say execution delays and weak shareholder communication are undermining confidence.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

A newly disclosed convertible-note financing and proposed increase in authorized shares have fueled concerns about heavy dilution, triggering sharp selling and criticism of managements communication. Some traders see the funding as necessary to advance data-center projects, while others worry that ongoing cash needs could bring further dilution.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys better-than-expected quarterly results, supported by parks strength and improving streaming profitability, have renewed bullish interest and fueled breakout chatter. Traders remain divided, with optimists pointing to stronger execution and skeptics citing years of range-bound performance and nearby resistance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Did KPRX Stock Surge 17% Pre-Market Today?

Equity

The company announced a $24 million private placement, led by Perceptive Advisors and ADAR1 Capital Management.

Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders

Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting...

Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should Know

Kiora Pharmaceuticals (KPRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Reported GAAP EPS of -$0.34 up 37.04% YoY

Kiora Pharmaceuticals continues to incur net losses while facing clinical trial execution risks and dependence on the successful completion of strategic transactions to secure additional capital for future operational needs.

Kiora Pharmaceuticals strengthened its financial position with a $24.0 million private placement, extending its operating runway into late 2028 while advancing clinical trials for KIO-301 with fully reimbursed development costs.

Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.

Kiora Pharmaceuticals Inc

Bullish Sentiment

<ul class="summary-bullets"><li>The financing includes $5 million in upfront proceeds and $19 million tied to the exercise of warrants.</li><li>Funds will be used to support general operations, business development, and ongoing research and development, the company said.</li><li>Recently, Kiora’s trial to treat retinitis pigmentosa entered the patient dosing phase.</li></ul>Shares of Kiora Pharmaceuticals, Inc. (KPRX) jumped more than 17% in pre-market trading on Tuesday after the company unveiled a $24 million private placement deal, signaling fresh support for its ongoing eye disease treatment pipeline.If the premarket levels hold after the opening bell, <a href="https://stocktwits.com/symbol/KPRX">KPRX shares</a> would trade at their highest levels in more than two months.<h2 class="st-heading-2">KPRX To Receive $5 Million Upfront</h2>The financing includes $5 million in upfront proceeds, with an additional $19 million tied to the potential exercise of milestone-based warrants. The investment was led by Perceptive Advisors and ADAR1 Capital Management.The offering was priced at-the-market, with each share and prefunded warrant sold together at $2.543. These include short-term Tranche A-1 warrants and longer-term Tranche A-2 warrants, both exercisable at $1.94 per share. The Tranche A-2 warrants are valid for up to four years, but their term shortens to 30 days once any of Kiora completes enrolment in a Phase 3 trial.KPRX stock closed at $2.02 on Monday.Kiora said it plans to use the initial funds to support general operations, business development, and ongoing research and development.Recently, Kiora advanced its pipeline with KIO-301 entering patient dosing in the Phase 2 ABACUS-2 trial for retinitis pigmentosa, a rare disease that causes retinal degeneration.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes.Chatter was mixed, with one user calling the placement “solid news.”<stembedurl>https://stocktwits.com/The_Assassin/message/649554703</stembedurl>Another user expects the stock to fall below $1 by the end of the week.<stembedurl>https://stocktwits.com/Shortski/message/649556539</stembedurl>Year-to-date, the stock has climbed by around 2%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Last week, Baird maintained AYI’s ‘neutral’ rating but cut price target to $320 from $375. (Representative image: Getty Images)

Kiora Pharmaceuticals (KPRX) - The company announced a $24 million private placement, led by Perceptive Advisors and ADAR1 Capital Management.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.56
Prev Close	$1.76
Open	$1.78
Dividend Yield	0.00%
50-Day Moving Average	$2.50
Beta	0.79
Avg. Volume	13,456.54
PE Ratio	-0.59

52-Week High	$2.91
52-Week Low	$1.55
Market Capitalization	$6.9M
EPS (Annual)	-$2.60
Price to Book	0.41
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

KPRX Fundamentals